ClinicalTrials.gg
CompletedNCT01631474Updated Nov 16, 2020Results posted

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

A Phase 2 interventional study of CB-03-01 and Vehicle in Acne Vulgaris, sponsored by Intrepid Therapeutics, Inc.. Completed at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by Intrepid Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
6th of 19
363 · median 50
Started
2012
the only one that year
Phase 2
3 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
2 of 19
Intrepid Therapeutics, Inc.

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • anti-androgen
  • clascoterone
  • cassiopea
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or non-pregnant female. Females must be , surgically sterile or using highly effective methods.
  • Subject has provided written and verbal /assent.
  • Subject has facial acne vulgaris (including the nose).
  • Subject is willing to comply with study instructions and return to the clinic for required visits.
  • Subject has used the same type and brand of make-up, other facial products (including cleanser) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the study start and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, lactating, or is planning to become pregnant during the study.
  • Subject is currently enrolled in an drug or device study.
  • Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the study start.
  • Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial
  • Subject has used any of the following topical anti-acne preparations or procedures on the face:

    • Topical anti-acne treatments including but not limited to over-the-counter acne cleaners or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based products, and salicylic acid within two weeks of the initiation of treatment.
    • Retinoids, including tazarotene, adapalene, tretinoin, within four weeks of the initiation of treatment.
    • Light treatments, microdermabrasion or chemical peels within eight weeks of the initiation of treatment.
  • Subject has used the following systemic anti-acne medications:

    • Corticosteroids (including intramuscular and intralesional injections) within four weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least four weeks prior to the initiation of treatment).
    • Antibiotics within four weeks of the initiation of treatment with the exception of five days or less of antibiotic therapy during this period, but with no antibiotics use permitted within one week prior to the initiation of treatment.
    • Spironolactone within eight weeks of the initiation of treatment with the exception of five days or less of spironolactone therapy during this period, but with no spironolactone use permitted within one week prior to the initiation of treatment.
    • Retinoid therapy within six months of the initiation of treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Low-dose active, BID

    low dose of CB-03-01, 0.1% applied twice a day

    Drug: CB-03-01

  • Experimental
    Medium-dose active, BID

    medium dose of CB-03-01, 0.5% applied twice a day

    Drug: CB-03-01

  • Experimental
    High-dose active, QD

    high dose of CB-03-01, 1% applied once a day

    Drug: CB-03-01

  • Experimental
    High-dose active, BID

    high dose of CB-03-01, 1% applied twice a day

    Drug: CB-03-01

  • Placebo comparator
    Vehicle, QD or BID

    vehicle cream, applied once or twice a day

    Drug: Vehicle

Interventions

  • Topical cream, applied once a day

    Also known as: clascoterone

  • DrugVehicle

    Topical cream, applied once or twice a day

  • Topical cream, applied twice a day

    Also known as: clascoterone

06

What researchers measure

Primary outcomes

  1. Investigator's Global Assessment (IGA) "Success" - Week 12

    Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of "clear" or "almost clear" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).

    Time frame: Baseline and Week 12

  2. Inflammatory and Non-Inflammatory Lesion Counts - Week 12

    Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Inflammatory and Non-Inflammatory Lesion Counts - Week 8

    Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.

    Time frame: Baseline and Week 8

  2. Percent Change in Lesion Counts - Weeks 8 and 12

    Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.

    Time frame: Week 8 and Week 12

  3. IGA "Success" - Week 8

    Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 ("success" as defined in the primary endpoints section).

    Time frame: Baseline and Week 8

  4. IGA "Clear" or "Almost Clear" - Weeks 4, 8 and 12

    Count and percentage of subjects who are "clear" or "almost clear" (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.

    Time frame: Weeks 4, 8, and 12

07

Results

Posted Nov 16, 2020

Participant flow

Participant flow — Overall Study
MilestoneLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Started7276707075
Completed5864615962
Not completed141291113
Withdrew: Lost to follow-up85755
Withdrew: Withdrawal by subject44265
Withdrew: Lack of efficacy22002
Withdrew: Noncompliance with study drug00001
Withdrew: Adverse event01000

Outcome measures

PrimaryInvestigator's Global Assessment (IGA) "Success" - Week 12

Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of "clear" or "almost clear" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Investigator's Global Assessment (IGA) "Success" - Week 12
ParticipantsLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Investigator's Global Assessment (IGA) "Success" - Week 1253262
PrimaryInflammatory and Non-Inflammatory Lesion Counts - Week 12

Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · lesions
Inflammatory and Non-Inflammatory Lesion Counts - Week 12
lesionsLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Inflammatory lesions-8.3 ± 14.63-5.8 ± 11.99-10.1 ± 12.53-12.3 ± 14.43-9.1 ± 13.67
Non-inflammatory lesions-8.7 ± 18.16-6.1 ± 29.22-8.4 ± 21.55-15.5 ± 20.48-6.7 ± 19.65
SecondaryInflammatory and Non-Inflammatory Lesion Counts - Week 8

Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.

Time frame:
Baseline and Week 8
Reported as:
Mean · lesions
Inflammatory and Non-Inflammatory Lesion Counts - Week 8
lesionsLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Inflammatory lesions-11.9 ± 8.84-7.2 ± 12.03-7.2 ± 17.21-11.5 ± 11.19-11.3 ± 12.71
Non-inflammatory lesions-7.0 ± 13.76-6.7 ± 16.33-3.2 ± 37.01-13.6 ± 17.99-8.3 ± 17.12
SecondaryPercent Change in Lesion Counts - Weeks 8 and 12

Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.

Time frame:
Week 8 and Week 12
Reported as:
Mean · percentage of change
Percent Change in Lesion Counts - Weeks 8 and 12
percentage of changeLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Inflammatory lesions (Week 8)-40.6 ± 28.20-26.6 ± 37.35-27.5 ± 41.44-41.1 ± 36.54-36.0 ± 35.01
Inflammatory lesions (Week 12)-26.8 ± 50.78-21.3 ± 45.33-32.5 ± 35.51-41.8 ± 52.25-28.4 ± 41.88
Non-inflammatory lesions (Week 8)-18.3 ± 34.50-19.5 ± 36.49-10.5 ± 57.13-33.5 ± 39.26-24.3 ± 43.23
Non-inflammatory lesions (Week 12)-24.3 ± 38.69-16.9 ± 55.66-19.5 ± 40.75-34.1 ± 46.95-19.5 ± 47.43
SecondaryIGA "Success" - Week 8

Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 ("success" as defined in the primary endpoints section).

Time frame:
Baseline and Week 8
Reported as:
Count of participants · Participants
IGA "Success" - Week 8
ParticipantsLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
IGA "Success" - Week 813142
SecondaryIGA "Clear" or "Almost Clear" - Weeks 4, 8 and 12

Count and percentage of subjects who are "clear" or "almost clear" (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.

Time frame:
Weeks 4, 8, and 12
Reported as:
Count of participants · Participants
IGA "Clear" or "Almost Clear" - Weeks 4, 8 and 12
ParticipantsLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Week 431572
Week 834264
Week 1264394

Adverse events

Collected over Adverse events (AEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-dose Active, BID0/72 (0%)0/72 (0%)12/72 (16.7%)
Medium-dose Active, BID0/76 (0%)0/76 (0%)18/76 (23.7%)
High-dose Active, QD0/70 (0%)0/70 (0%)9/70 (12.9%)
High-dose Active, BID0/70 (0%)0/70 (0%)5/70 (7.1%)
Vehicle, QD or BID0/75 (0%)0/75 (0%)5/75 (6.7%)
Most frequent other events
Most frequent other events
EventLow-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BID
Upper respiratory tract infectionInfections and infestations6/728/762/703/702/75
NasopharyngitisInfections and infestations1/720/764/701/700/75
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/724/761/700/700/75
PyrexiaGeneral disorders0/722/762/700/700/75
HeadacheNervous system disorders2/721/760/700/702/75
LacerationInjury, poisoning and procedural complications2/721/760/700/700/75
Nasal congestionRespiratory, thoracic and mediastinal disorders0/722/760/701/701/75

Baseline characteristics

ITT Population. The ITT population included all subjects enrolled in the study who were randomized and dispensed test article.

Age, Continuous
Age, Continuous(years)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
Mean19.8 ± 5.7720.4 ± 6.3118.3 ± 6.1421.0 ± 6.2219.2 ± 5.2519.7 ± 5.99
Sex: Female, Male
Sex: Female, Male(Participants)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
Female3642383743196
Male3634323332167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
Hispanic or Latino22206151376
Not Hispanic or Latino5056645562287
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
American Indian or Alaska Native010203
Asian1344416
Native Hawaiian or Other Pacific Islander010012
Black or African American121416201274
White5854504253257
More than one race120249
Unknown or Not Reported010012
Baseline IGA
Baseline IGA(Participants)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
0 - Clear000000
1 - Almost clear000000
2 - Mild10615181160
3 - Moderate5662443253247
4 - Severe6811201156
Baseline lesions counts
Baseline lesions counts(lesions)Low-dose Active, BIDMedium-dose Active, BIDHigh-dose Active, QDHigh-dose Active, BIDVehicle, QD or BIDTotal
Inflammatory lesions29.9 (20 to 74)29.0 (20 to 74)31.9 (20 to 72)28.6 (20 to 63)30.5 (20 to 75)30.0 (20 to 75)
Non-inflammatory lesions43.5 (21 to 99)44.5 (21 to 98)46.7 (21 to 91)47.2 (20 to 98)43.9 (20 to 99)45.2 (20 to 99)
08

Study locations

13 sites
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • International Clinical Research - US, LLC
    Sanford, Florida, United States
  • Gwinnett Clinical Research Center, Inc.
    Snellville, Georgia 30078, United States
  • Altman Dermatology Associates
    Arlington Heights, Illinois 60005, United States
  • Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Marina I. Peredo, M.D., PC
    Smithtown, New York, United States
  • Penn State Milton S. Hershey Medical Center - Dept. of Dermatology
    Hershey, Pennsylvania 17033, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island, United States
  • J & S Studies
    College Station, Texas 77845, United States
  • UT Houston Health Science Center
    Houston, Texas 77030, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23507, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 6 years 9 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2012
First posted
Jun 29, 2012
Start
Jun 2012
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results delay requested
Mar 27, 2015
Results first posted
Nov 16, 2020
Last update
Nov 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01631474
Lead sponsor
Intrepid Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2012
Start date
Jun 2012
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Nov 16, 2020
Last update
Nov 16, 2020

Study contacts

R&D Cassiopea
study director · Cassiopea S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion